Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 831-845 , October 2008

The antiphospholipid syndrome

References 

  1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis and Rheumatism. 1999;42:1309–1311
  2. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis and Rheumatism. 2000;43:440–443
  3. Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology. 2003;42:200–213
  4. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis and Rheumatism. 2002;46:1019–1027
  5. Tektonidou MG, Moutsopoulos HM. Osteoarticular manifestations of antiphospholipid syndrome. Rheumatic Diseases Clinics of North America. 2006;32:523–535
  6. Espinosa G, Santos E, Cervera R, et al. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine. 2003;82:106–118
  7. Deschiens MA, Conard J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke. 1996;27:1724–1730
  8. Palmowski-Wolfe AM, Denninger E, Geisel J, et al. Antiphospholipid antibodies in ocular arterial and venous occlusive disease. Ophthalmologica. 2007;221:41–46
  9. Hirohata Y, Murata A, Abe S, Otsuki M. Portal vein thrombosis associated with antiphospholipid syndrome. Journal of Gastroenterology. 2001;36:574–578
  10. Opatrny L, David M, Kahn SR, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. The Journal of Rheumatology. 2006;33:2214–2221
  11. Dreyfus M, Hedelin G, Kutnahorsky R, et al. Antiphospholipid antibodies and preeclampsia: a case-control study. Obstetrics and Gynecology. 2001;97:29–34
  12. Lee RM, Brown MA, Branch DW, et al. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in preeclampsia. Obstetrics and Gynecology. 2003;102:294–300
  13. Branch DW, Porter TF, Rittenhouse L, et al. Antiphospholipid antibodies in women at risk for preeclampsia. American Journal of Obstetrics and Gynecology. 2001;184:825–832
  14. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827–1832
  15. Wong RC, Australasian aCL Working Party . Consensus guidelines for anticardiolipin antibody testing. Thrombosis Research. 2004;114:559–571
  16. Tincani A, Allegri F, Balestrieri G, et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thrombosis Research. 2004;114:553–558
  17. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis. 2006;4:295–306
  18. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation. 2000;102:3137–3147
  19. Male C, Foulon D, Hoogendoorn H, et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood. 2005;106:4152–4158
  20. Erkan D, Derksen WJ, Kaplan V, et al. Real world experience with antiphospholipid antibody tests: how stable are results over time?. Annals of the Rheumatic Diseases. 2005;64:1321–1325
  21. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. Journal of Thrombosis and Haemostasis. 2005;3:1231–1238
  22. Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. Journal of Thrombosis and Haemostasis. 2005;3:1160–1165
  23. Lopez LR, Dier KJ, Lopez D, et al. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. American Journal of Clinical Pathology. 2004;121:142–149
  24. Von Scheven E, Glidden DV, Elder ME. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis and Rheumatism. 2002;47:414–420
  25. Faden D, Tincani A, Tanzi P, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 1997;73:37–42
  26. Forastiero RR, Martinuzzo ME, Cerrato GS, et al. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thrombosis and Haemostasis. 1997;78:1008–1014
  27. Lee RM, Emlen W, Scott JR, et al. Anti-beta2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome. American Journal of Obstetrics and Gynecology. 1999;181:642–648
  28. Neville C, Rauch J, Kassis J, et al. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thrombosis and Haemostasis. 2003;90:108–115
  29. Lee EY, Lee CK, Lee TH, et al. Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis?. Thrombosis Research. 2003;111:29–32
  30. Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thrombosis and Haemostasis. 2005;93:1147–1152
  31. Ruffatti A, Tonello M, Del Ross T, et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thrombosis and Haemostasis. 2006;96:337–341
  32. Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Annals of the Rheumatic Diseases. 2007;66:927–930
  33. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the second international workshop for identification of lupus anticoagulants. On behalf of the subcommittee on lupus anticoagulants/antiphospholipid antibodies of the ISTH. Thrombosis and Haemostasis. 1995;74:1597–1603
  34. Lockwood CJ, Romero R, Feinberg RF, et al. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. American Journal of Obstetrics and Gynecology. 1989;161:369–373
  35. de Laat B, Derksen RH, van Lummel M, et al. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006;107:1916–1924
  36. Pasquali JL, Poindron V, Korganow AS, Martin T. Pathogenesis of the antiphospholipid syndrome. La Presse médicale. 2007;36:667–673
  37. Lieby P, Soley A, Levallois H, et al. The clonal analysis of anticardiolipin antibodies in a single patient with primary antiphospholipid syndrome reveals an extreme antibody heterogeneity. Blood. 2001;97:3820–3828
  38. Petri M. Epidemiology of the antiphospholipid antibody syndrome. Journal of Autoimmunity. 2000;15:145–151
  39. Vila P, Hernández MC, López-Fernández MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thrombosis and Haemostasis. 1994;72:209–213
  40. Crowther MA, Wisloff F. Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thrombosis Research. 2005;115:3–8
  41. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus. 2002;11:269–275
  42. Panzer S, Gschwandtner ME, Hütter D, et al. Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome. Annals of Hematology. 1997;74:239–242
  43. Schallmoser K, Rosin C, Vormittag R, et al. Specificities of platelet autoantibodies and platelet activation in lupus anticoagulant patients: a relation to their history of thromboembolic disease. Lupus. 2006;15:507–514
  44. Diz-Küçükkaya R, Hacihanefioğlu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98:1760–1764
  45. Rottem M, Krause I, Fraser A, et al. Autoimmune hemolytic anaemia in the antiphospholipid syndrome. Lupus. 2006;15:473–477
  46. Arvieux J, Schweizer B, Roussel B, Colomb MG. Autoimmune haemolytic anaemia due to anti-phospholipid antibodies. Vox Sanguinis. 1991;61:190–195
  47. Brey RL, Chapman J, Levine SR, et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus. 2003;12:508–513
  48. Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis and Rheumatism. 1999;42:728–734
  49. Menon S, Jameson-Shortall E, Newman SP, et al. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis and Rheumatism. 1999;42:735–741
  50. Tektonidou MG, Varsou N, Kotoulas G, et al. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Archives of Internal Medicine. 2006;166:2278–2284
  51. Chapman J, Abu-Katash M, Inzelberg R, et al. Prevalence and clinical features of dementia associated with the antiphospholipide syndrome and circulating anticoagulants. Journal of the Neurological Sciences. 2002;203–204:81–84
  52. Asherson RA, Khamashta MA, Gil A, et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. The American Journal of Medicine. 1989;86:391–399
  53. Westerman EM, Miles JM, Backonja M, Sundstrom WR. Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event. Arthritis and Rheumatism. 1992;35:1038–1041
  54. Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine. 1997;76:203–212
  55. Tietjen GE, Day M, Norris L, et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study. Neurology. 1998;50:1433–1440
  56. Verrot D, San-Marco M, Dravet C, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. The American Journal of Medicine. 1997;103:33–37
  57. Hojnik M, George J, Ziporen L, Schoerfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579–1587
  58. Margarita A, Batuca J, Scenna G, et al. Subclinical atherosclerosis in primary antiphospholipid syndrome. Annals of the New York Academy of Sciences. 2007;1108:475–480
  59. Francès C, Niang S, Laffitte E, et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis and Rheumatism. 2005;52:1785–1793
  60. Uthman I, Khamashta M. Antiphospholipid syndrome and the kidneys. Seminars in Arthritis and Rheumatism. 2006;35:360–367
  61. Tektonidou MG, Sotsiou F, Nakopoulou L, et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis and Rheumatism. 2004;50:2569–2579
  62. Asherson RA. The catastrophic antiphospholipid (Asherson's) syndrome. Autoimmunity Reviews. 2006;6:64–67
  63. Asherson RA, Espinosa G, Menahem S, et al. Relapsing Catastrophic Antiphospholipid Syndrome: Report of Three Cases. Seminars in Arthritis and Rheumatism. 2008;37:366–372
  64. Miesbach W, Asherson RA, Cervera R, et al. The catastrophic antiphospholipid (Asherson's) syndrome and malignancies. Autoimmunity Reviews. 2006;6:94–97
  65. Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood. 2005;105:1964–1969
  66. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106:2340–2346
  67. Lutters BC, Derksen RH, Tekelenburg WL, et al. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. The Journal of Biological Chemistry. 2003;278:33831–33838
  68. Cesarman-Maus G, Ríos-Luna NP, Deora AB, et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood. 2006;107:4375–4382
  69. Rand JH, Wu XX, Quinn AS, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. The American Journal of Pathology. 2003;163:1193–1200
  70. Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. Journal of Reproductive Immunology. 2008;77:51–56
  71. Lieby P, Poindron V, Roussi S, et al. Pathogenic antiphospholipid antibody: an antigen-selected needle in a haystack. Blood. 2004;15(104):1711–1715
  72. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. The New England Journal of Medicine. 2003;349:1133–1138
  73. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Journal of Thrombosis and Haemostasis. 2005;3:848–853
  74. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of anticoagulation study group. The American Journal of Medicine. 1998;104:332–338
  75. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. The American Journal of Medicine. 1996;100:530–536
  76. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. The New England Journal of Medicine. 1995;332:993–997
  77. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA : The Journal of the American Medical Association. 2004;291:576–584
  78. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. The New England Journal of Medicine. 2001;345:1444–1451
  79. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database of Systematic Reviews (Online). 2005 Apr 18;CD002859
  80. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstetrics and Gynecology. 2002;100:408–413
  81. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:627S–644S
  82. Tincani A, Branch W, Levy RA, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus. 2003;12:524–529
  83. Deruelle P, Coulon C. The use of low-molecular-weight heparins in pregnancy–how safe are they?. Current Opinion in Obstetrics & Gynecology. 2007;19:573–577
  84. Erkan D, Merrill JT, Yazici Y, et al. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis and Rheumatism. 2001;44:1466–1467
  85. Alarcón-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus. 2003;12:499–503

PII: S1521-6942(08)00097-1

doi: 10.1016/j.berh.2008.08.008

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 831-845 , October 2008

Article Tools